Giuseppe Filardo, MD, PhD, is a Professor at the Faculty of Biomedical Sciences, USI, Head of Clinical Research at the Ospedale Regionale of Lugano, Switzerland, and the Senior Research Advisor at the Rizzoli Orthopedic Institute for the Applied and Translational Research Center, Bologna, Italy. He is one of the most prolific authors in the orthobiologic field with over 400 publications. His research activities focus on the study of orthobiologics for the musculoskeletal system, particularly the development of minimally invasive treatments and the identification of the potential, limits, and indications of the emerging regenerative approaches.

Bert R. Mandelbaum is double board certified in orthopedic surgery and orthopedic sports medicine. He received his MD degree from Washington University in St. Louis, then completed his residency at Johns Hopkins Hospital. He is widely recognized as one of the world's foremost experts in soccer injury. He has served as a head team physician on the men's and women's teams for multiple World Cups and Olympic Games.

George Muschler is an expert in reconstructive surgery for arthritis, failed joint replacements, treatment of fractures and limb deformities, and musculoskeletal oncology. He is recognized internationally as a leader in stem cell biology, tissue engineering and regenerative medicine. He has lead a series of inter-disciplinary and inter-institutional programs, as well as committees in the Orthopaedic Research Society, international Society for Cell and Gene Therapy, and the American Academy of Orthopaedeic Surgeons.

Scott Rodeo is a clinician-scientist at the Hospital for Special Surgery (HSS), with appointments in the Department of Orthopedics and the Research Department. He is a Professor of Orthopedic Surgery at Weill Cornell Medical College and Co-Chief Emeritus of the Sports Medicine Service at the Hospital for Special Surgery. He serves as Vice Chairof Orthopaedic Research and Director of the HSS Center for Regenerative Medicine. He specializes in sports medicine injuries of the knee, shoulder, ankle and elbow and performs arthritis surgery on the knee and shoulder, including joint replacement surgery. Rodeo serves as Head Team Physician for the New York Giants Football Team. .

Provides a comprehensive overview of the available orthobiologics treatments

Adopts a clinically oriented approach with a focus on injectable orthobiologics

Presents both the potential and limitations based on the latest literature

I. Injectable OrthoBiologics: Formulations and Rationale 1. Bone marrow-derived cultured stromal cells and Bone Marrow Concentrate.- 2. Adipose-derived cultured stromal cells and Stromal Vascular Fraction from adipose tissue.- 3. Synovial-derived cultured stromal cells.- 4. Amniotic, Placenta, and Umbilical cord-derived cultured stromal cells.- 5. Allogeneic cells: pros and cons.- 6. Steroid hormones.- 7. Cytokines, chemokines, alpha-2-macroglobulin, growth factors.- 8. Platelet-rich plasma: leucocyte-rich, leukocyte-poor, autologous conditioned serum, autologous protein solution.- 9. Amniotic tissue extract, placenta tissue extract.- 10. Extracellular vesicles (exosomes).- II. Injectable OrthoBiolologics: evaluation methods and results based on pathology and anatomy.- 11. Rotator cuff tendinopathy: cell therapy.- 12. Rotator cuff tendinopathy: biologics.- 13. Tennis elbow: cell therapy.- 14. Tennis elbow: cell therapy biologics.- 15. Patellar tendinopathy: cell therapy.- 16. Patellar tendinopathy: biologics.- 17. Achilles tendinopathy: cell therapy.- 18. Achilles tendinopathy: biologics.- 19. Plantar Fasciitis: cell therapy.- 20. Plantar Fasciitis: biologics.- 21. Ligament lesions: cell therapy.- 22. Ligament lesions: biologics.- 23. Meniscal lesions: cell therapy.- 24. Meniscal lesions: biologics.- 25. Muscle lesions: cell therapy.- 26. Muscle lesions: biologics.- 27. Fractures (incl. Nonunions): cell therapy.- 28. Fractures (incl. Nonunions): biologics.- 29. Cartilage lesions and Osteoarthritis of the knee: cell therapy.- 30. Cartilage lesions and Osteoarthritis of the knee: biologics.- 31. Cartilage lesions and Osteoarthritis of the hip and ankle: cell therapy.- 32. Cartilage lesions and Osteoarthritis of the hip and ankle: biologics.- III. Future directions 33. Pluripotent stem cells: Embryonic/Fetal stem cells and inducedpluripotent stem (iPS) cells.- 34. Gene therapy.- 35.Stimulation of the intrinsic stromal cell niche.- 36 Conclusions.